Home » Newsletters » BioWorld Science

BioWorld Science

July 15, 2016

View Archived Issues

ZIOPHARM plans phase I study of CD33 CAR T-cell therapy

MJFF, van Andel Research and Cure Parkinson's Trust to study nilotinib in Parkinson's disease

IntelGenx starts phase I trial of montelukast for the treatment of neurodegenerative diseases

Oncodesign launches phase 0/I trial for ODS-2004436 radiotracer

Mutations in TRMT10C identified as a cause of mitochondrial disease

Aptinyx starts dosing in phase I trial for NYX-2925

Merck & Co. patents BTK inhibitors

OncoArendi Therapeutics describes arginase inhibitors

King's College London discloses retinoid RARbeta receptor agonists

Revlimid approved in Europe for relapsed or refractory MCL

Hitgen reports HDAC inhibitors

NovoBiotic Pharmaceuticals receives grant from NIAID to advance teixobactin program

Dethree Res, J-Pharma and Nippon Chemiphar present URAT1 inhibitors

Update on U.S. regulatory filing for Raxone in Duchenne muscular dystrophy

Juno Therapeutics acquires RedoxTherapies

Boehringer Ingelheim announces collaboration with the University of Dundee

Three organizations merge to form Lupus Research Alliance

ArmaGen presents data on AGT-182 for Hunter syndrome

GSK exercises option under respiratory disease collaboration with Five Prime

Plex Pharmaceuticals obtains funding to develop compounds for Parkinson's disease

NTRK2 shows promise as a therapeutic target for astrocytoma

Disruption of TRIP8b-HCN interaction may induce antidepressant-like behavior

Tyrosine kinase inhibitor shows promise in Parkinson's disease patients

FDA advisory committee recommends approval of biosimilar etanercept

New panel shows promise for infection diagnosis

An RYR1 mutation is associated with bleeding abnormalities

NIH expands investment to advance basic medical research toward HIV cure

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 4, 2026.
University of Western Australia patents 5-HT2A/B modulators
BioWorld Science
University of Western Australia has identified new lysergic acid diethylamide (LSD) analogues acting as 5-HT2A and 5-HT2B modulators reported to be useful for the...
Alceptor Therapeutics discovers new α2B-adrenoceptor agonists
BioWorld Science
Alceptor Therapeutics Inc. has patented new pyrazol-5-amine α2B-adrenoceptor agonists reported to be useful for the treatment of pain and hypertension.
EQ-504 is AhR agonist for ulcerative colitis, related disorders
BioWorld Science
Activating the aryl hydrocarbon receptor (AhR) in immune cells enhances anti-inflammatory pathways and limits pathogenic immune responses. Equillium Inc. has...
Quintuple GLP-1–GIP–PPAR agonist for obesity and diabetes control
BioWorld
A new molecule combines the action of two incretins, GLP-1 and GIP, hormones that regulate glucose and appetite, with lanifibranor, a triple agonist of peroxisome...